Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
The Clinical and Laboratory Standards Institute has published “M54-APrinciples and Procedures for Detection of Fungi in Clinical Specimens-Direct Examination and Culture; Approved Guideline.” The document addresses the protocols for detecting fungi in clinical specimens and highlights direct microscopic examinations and fungal culturing methods.
Qiagen has submitted to the FDA its Therascreen EGFR RGQ PCR kit as a proposed companion diagnostic test to guide treatment with afatinib, an investigational oncology compound developed by Boehringer Ingelheim. The FDA has accepted afatinib for filing and granted it priority review as a proposed treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation detected by an FDA-approved test.
Smart Imaging Technologies’ Simagis Live Web Pathology Platform version 4.0, launched last month, makes the transition to digital pathology simple and affordable. With Simagis cloud software, pathologists can connect scanners to a private cloud server and start collaborating.
Insight Genetics has received from the National Cancer Institute two small business innovation research contracts to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients.
Computype, in partnership with Nautilus Systems, launched the Flexible Tube and Vial Feeder (Flex TVF), a system for automatic downstream tube and vial feeding that increases efficiency.
Chembio Diagnostics has received FDA approval to market its point-of-care Dual Path Platform (DPP) HIV 1/2 assay for the rapid detection of HIV-1/2 antibodies in oral fluid or blood samples.
Akonni Biosystems recently announced results from three preclinical studies verifying the efficacy of its TruDiagnosis molecular diagnostic platform. Akonni TruArray tests are for mid-multiplex molecular diagnostics deployed in near point-of-care settings.
Cellular Engineering Technologies and the nonprofit John Paul II Medical Research Institute (JP2MRI) are partnering to develop a private stem cell biobank. The collaboration will create more than 5,000 patient- and disease-specific stem cell lines and other human cell lines to advance drug discovery and offer personalized medicine. These cell lines are derived from adult sources and do not include embryonic stem cells.
Luminex has received FDA clearance for its xTAG gastrointestinal pathogen panel (GPP), which is a comprehensive molecular diagnostic assay that tests for greater than 90 percent of bacterial, viral, and parasitic causes of infectious gastroenteritis.
DiaSorin has received FDA clearance for its Liaison direct renin immunoassay to aid in the diagnosis and treatment of certain types of hypertension.
